Original Research Article

Evaluation of ustekinumab treatment in psoriasis and the potential effect of metabolic syndrome on treatment response: a single center retrospective study

Ömer Kutlu¹*, Hatice M. Eksioglu²

¹Department of Dermatology and Venereology, Usak University, School of Medicine, Usak, Turkey
²Department of Dermatology and Venereology, Ankara Training and Research Hospital, Ankara, Turkey

Received: 26 March 2020
Revised: 01 May 2020
Accepted: 06 May 2020

*Correspondence:
Dr. Ömer Kutlu,
E-mail: omerkutlu22@gmail.com

ABSTRACT

Background: Ustekinumab is a biological agent used in the treatment of psoriasis. This study evaluated the treatment response of psoriasis patients who received ustekinumab.

Methods: The study included nine patients with plaque-type psoriasis who received ustekinumab treatment. Clinical response of all patients was evaluated with psoriasis area and severity index (PASI), dermatology life quality index (DLQI), and psoriasis disability index (PDI) at 0, 4, 16, and 28 weeks. The patients were also evaluated for metabolic syndrome and its effect on treatment response.

Results: A total of five male and four female patients with psoriasis vulgaris were included in the study. At the end of 28th weeks, 55% of the patients reached PASI 75 score. The mean PASI scores of the patients at weeks 0, 4, 16, 26 and 28 were 36.98±12.28, 8.86±9.06, 9.52±11.55, 3.55±3.61 and 6.98±6.40, respectively. Although not statistically significant, at the 28th weeks, the mean PASI, DLQI and PDI values of the patients with metabolic syndrome were higher than those without metabolic syndrome (p=0.505, p=0.314, p=0.786, respectively).

Conclusions: Ustekinumab is an effective treatment option for patients with psoriasis who resistant to conventional and biological treatments. In resistant cases to the ustekinumab, the routine treatment interval should be reduced. Psoriasis patients with accompanying metabolic syndrome may have a lower response rate than those without metabolic syndrome to biological agents.

Keywords: PASI score, Quality of life, Ustekinumab, Metabolic syndrome

INTRODUCTION

Biological agents have been used for certain diseases in dermatological diseases since they were approved for the treatment of moderate to severe psoriasis in 2003.¹ They are protein molecules produced by recombinant DNA technology that target specific points in the immunopathogenesis of the diseases.²³ Ustekinumab (UST) is a biological agent that inhibits signaling pathways activated by IL-12/23. It is a human IgG1k monoclonal antibody that binds with specificity to the p40 protein subunit used by both the interleukin (IL)-12 and IL-23 cytokines.⁴⁵ Since its approval for psoriasis in 2009 by the FDA, it has been compared with other biological agents in numerous studies.⁶⁷ In this study, the clinical and demographic characteristics of patients who received UST due to resistance to previous treatments were evaluated. Psoriasis area and severity index (PASI),
psoriasis disability index (PDI) and the Dermatology Life Quality Index (DLQI) were used to assess the efficacy of UST. Furthermore, to our knowledge, there is no sufficient studies on the relationship between metabolic syndrome and UST treatment. Therefore, we also investigated the relationship between metabolic syndrome and UST treatment in patients with psoriasis.

METHODS

Study design

This is a single-center, retrospective study. The study included 9 plaque-type psoriasis patients who were resistant to conventional/anti-TNF agent’s treatment and received UST treatment for at least six months. The dose of UST for an adult patient with psoriasis weighing up to 100kg was 45mg (one injection) at week 0, one injection at week 4 and then an injection every 12 weeks from then on. For patients weighing more than 100kg, the dose was 90mg (two injections) and was given at the same time as the lower dose (i.e. week 0, week 4, and then every 12 weeks from then on). The clinical and demographic characteristics of the patients were described and also PASI, DLQI and PDI scores were investigated at week 0, 4, 16, 26, and 28. At the end of 26 weeks the PASI score was evaluated due to flare up of psoriasis two weeks before previous injections.

Psoriasis Disability Index and Dermatology Life Quality Index

DLQI is a test consisting of 10 questions that are specific to skin diseases. The mean DLQI score (maximum 30) is ranged from 0 to 0.5 in the normal population. Compared to the normal population, DLQI has been shown to have a very high specificity in psoriasis. PDI is the first survey-based validated scale defined in psoriasis that has been translated into more than 20 languages worldwide. It is still popular and is used throughout the world to evaluate psoriasis.

RESULTS

Five men and 4 women patients with plaque type psoriasis were included in this study.

Table 1: Demographic and clinical characteristics of patients receiving ustekinumab.

| S. no. | Gender/age | BMI | Previous biological treatment presence | The presence of Pa | Presence of Ms | PASI score (0/28th week) | PASI 75 response | DLQI score (0/28 week) | Concomitant systemic treatment |
|--------|------------|-----|----------------------------------------|-------------------|---------------|-------------------------|----------------|------------------------|-------------------------------|
| 1      | M/50       | 39.44 | IFX                                    | None              | Yes           | 41.1/3.9                | Yes           | 7/0                    | MTX                           |
| 2      | F/63       | 28.76 | None                                   | None              | None          | 40.4/14.4               | None          | 4/1                    | None                          |
| 3      | F/44       | 27.34 | IFX                                    | None              | None          | 21.0/9.2                | None          | 6/6                    | None                          |
| 4      | M/55       | 28.36 | ETC                                    | None              | None          | 54.0/6.3                | Yes           | 9/6                    | ACT                           |
| 5      | M/20       | 21.55 | None                                   | Yes               | None          | 48.3/1.0                | Yes           | 15/0                   | None                          |
| 6      | M/40       | 25.35 | None                                   | Yes               | None          | 25.3/0.0                | Yes           | 2/4                    | None                          |
| 7      | F/49       | 31.60 | ETC, IFX, ADA                          | Yes               | Yes           | 40.0/17.6               | None          | 9/21                   | LEF                           |
| 8      | M/48       | 24.78 | IFX, ETC                               | Yes               | None          | 33.0/10.4               | None          | 16/5                   | None                          |
| 9      | F/34       | 33.62 | IFX, ADA                               | Yes               | Yes           | 24.8/0.0                | Yes           | 27/0                   | None                          |

ADA=adalimumab BMI=body mass index, PASI: psoriasis area and severity index, DLQI: dermatology life quality index, ETC=etanercept, IFX=infliximab, LEF=leflunamid, Ms=metabolic syndrome, MTX=methotrexate, Pa=psoriatic arthritis.
Table 2: Changes in psoriasis area and severity index score during ustekinumab treatment.

| PASI score | Week 0 | Week 4 | Week 16 | Week 26 | Week 28 |
|------------|--------|--------|---------|---------|---------|
| Mean       | 36.90  | 8.87   | 9.52    | 3.56    | 6.97    |
| Median     | 40.00  | 8.80   | 6.60    | 2.00    | 6.30    |
| SD         | 12.28  | 9.07   | 11.55   | 3.61    | 6.40    |
| Minimum    | 21.00  | 0.00   | 0.60    | 0.00    | 0.00    |
| Maximum    | 59.00  | 29.9   | 38.70   | 10.20   | 17.60   |

PASI: psoriasis area severity index.

Table 3: Changes in dermatology quality of life index and psoriasis disability index scores during ustekinumab treatment.

| Variables | DLQI/PDI score |
|-----------|----------------|
| Weeks     | Mean | Median | SD     | Minimum | Maximum |
| 0         | 13.11/24.67 | 10.00/24.00 | 8.06/11.12 | 4/9 | 27/45 |
| 4         | 4.11/12.89 | 2.00/12.00 | 5.13/9.44 | 0/2 | 13/31 |
| 16        | 4.22/9.33  | 2.00/7.00  | 6.74/10.01 | 0/0 | 21/27 |
| 28        | 1.86/8.75  | 1.00/4.50  | 2.27/10.99 | 0/0 | 6/31  |

DLQI: dermatology quality of life index, PDI: psoriasis disability index.

Table 4: Psoriasis disability index, psoriasis area severity index, and dermatology quality of life index scores of patients with and without metabolic syndrome at the end of the 28th weeks.

| Variables | Patients with metabolic syndrome (n=3) | Patients without metabolic syndrome (n=6) |
|-----------|----------------------------------------|-------------------------------------------|
|           | PDI | PASI | DLQI | PDI | PASI | DLQI |
| Mean      | 16.50 | 7.16 | 8.33 | 6.17 | 6.89 | 2.17 |
| Median    | 16.50 | 3.90 | 1.00 | 4.00 | 7.75 | 2.00 |
| SD        | 20.51 | 9.24 | 14.43 | 7.28 | 5.60 | 2.31 |
| Minimum   | 2.00 | 3.90 | 0.00 | 0.00 | 0.00 | 0.00 |
| Maximum   | 31.00 | 17.60 | 25.00 | 19.00 | 14.40 | 6.00 |

DLQI: dermatology quality of life index, PASI: psoriasis area severity index, PDI: psoriasis disability index.

The mean age of the patients was 44.78±12.4 years. In addition, the mean body mass index value of the patients was 28.9±5.3 kg/m² (minimum 21.5, maximum 39.4) while the mean duration of disease was 24.67±10.1 years (minimum 12, maximum 45). Five patients had psoriatic arthritis associated with psoriasis and 3 patients had metabolic syndrome. One patient received acitretin with UST since the 16th week of treatment, while the other two patients received methotrexate and leflunomide with UST since the first week. At the end of week 28, the number of patients achieving PASI 75 was 5 (55%) and the other 4 patients achieved PASI 50 response (Table 1).

The mean PASI, DLQI and PDI scores of the patients with metabolic syndrome were higher than those without metabolic syndrome at the end of the 28th week. However, there was no statistically significant difference between these two groups in terms of mean PASI, DLQI and PDI scores (p=0.505, p=0.314, p=0.786) (Table 4).

The mean PASI, DLQI and PDI scores of the patients receiving UST were recorded for each treatment session.

Figure 1: Changes in mean PDI, DLQI, and PASI values during 28 weeks of follow-up.
In this study, clinical responses during periods of follow-up were maintained through week 28. In addition to PASI score, periodic DLQI and PDI scores of patients were also calculated. Although not statistically significant, interestingly, while the mean PASI score of the nine patients who were admitted to the clinic at 26 weeks (2.5 months after the last injection) was 3.55±3.61, it was increased as 6.98±6.40 within two weeks (3 months after the last injection) (Figure 2). In this regard, it can be considered that the treatment interval should be reduced in patients with resistance to the 3 month-interval UST treatment. Further studies such as randomized controlled trials are required to elucidate this issue.

In the present study, DLQI and PDI scores correlated with PASI score and the maximum response to UST treatment was observed at week 26 compared with previous weeks (Figure 1). In this context, it can be speculated that UST may have a cumulative effect. The PASI 75 response was obtained in 55% of patients and PASI 50 response was obtained in all patients. Three out of the four patients who did not achieve the PASI 75 response, did not respond to previous anti-TNF treatments. The failure of these patients to achieve the PASI 75 response can be explained in several ways. Patients with the HLA-Cw6 polymorphism have a higher level of response to UST. The differences in HLA-Cw6 polymorphism in these patients may explain this change in response. However, it can be concluded that different pathways that trigger psoriasis may be at the forefront in these patients. In recent years, IL-17 has been found to play an active role in the pathogenesis of psoriasis. IL-17 was found to induce neutrophil chemoattractant chemokines and antimicrobial peptide expression, maintain chronic inflammation and induce psoriasis by upregulating the keratinocyte chemokine CCL20. In this context, biological agent therapies acting on the IL-17 pathway may be used in cases resistant to anti-TNF and UST treatments.

Another finding in this study was the response to UST treatment in patients with metabolic syndrome. There are no sufficient studies on the relationship between response to biological agents and the presence of metabolic syndrome in psoriasis. The cytokine dysregulation of TNF-alpha, IL-6, and, IL-17 caused by Th-1 and Th17 in psoriasis, can induce insulin resistance and obesity by antagonizing the insulin signalling pathway, as well as altering the expression of adipokine and increasing proliferation of epithelial keratinocytes. In contrast, hyperinsulinemia in metabolic syndrome may also induce angiogenesis and chronic inflammation leading to the formation of psoriasis. It has been reported that psoriasis will be more severe in patients with metabolic syndrome. In this study, mean PASI, DLQI and PDI scores of the patients with metabolic syndrome were 7.16±9.7, 8.3±14.43, and 16.5±20.5, while for patients without metabolic syndrome these scores were 6.9±5.6, 2.2±2.3 and, 6.17±7.2, respectively at the end of the 28 weeks (Figure 3). In this regard, it can be speculated that

DISCUSSION

Psoriasis is a chronic systemic autoimmune inflammatory disease that causes an increased turnover of skin cells. Psoriasis vulgaris represents its most common form, with a prevalence of 1-3% in the general population. The pathogenesis of psoriasis was initially defined as increased expression of Th1 cytokines such as IL-2, IFN-γ and TNF-α in psoriatic lesions. After IL-12 and IL-23 cytokines were shown to induce secretion of cytokines such as IL-2, 6, 17 and 22 by maturing Th1 and Th17 cells in the pathogenesis of psoriasis, IL-12/23 inhibitors were developed for treatment of the disease. Ustekinumab is known as an anti-IL12/23 IgG1 kappa human monoclonal antibody, approved by the FDA in 2009 for the treatment of psoriasis. Since its approval for the treatment of psoriasis, a number of clinical studies, which still preserve its popularity, have been conducted on the effectiveness and safety of UST. The most effective parameters that measure the efficacy of treatment in these studies are the DLQI score with the change in PASI score as in our study.
patients with psoriasis accompanying metabolic syndrome will have a lower response rate to UST treatment than those without metabolic syndrome. Optimal response from biological treatment can be achieved by overcoming obesity and insulin resistance. The main limitations of this study include a small sample size. This is a preliminary study, future studies with a larger number of patients will enable this subject to be examined in detail.

CONCLUSION

In conclusion, UST is an effective treatment option that can be used in patients with psoriasis who resistant to conventional and/or other biological treatments. In resistant cases, the routine treatment interval of 3 months for UST should be reduced. Lastly, patients with psoriasis accompanying metabolic syndrome may have a lower response rate to UST treatment than those without metabolic syndrome. This issue should be clarified by future studies that include large samples.

ACKNOWLEDGEMENTS

No sources of funding were used to conduct this study or prepare this manuscript. Study design: ÖK data collection: ÖK analysis: ÖK and manuscript preparation: ÖK, HME.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: The study was approved by the institutional ethics committee

REFERENCES

1. Smith CH, Anstey AV, Barker JN. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol. 2005;153(3):486-97.
2. Mehlis S, Gordon KB. From laboratory to clinic: rationale for biologic therapy. Dermatol Clin. 2004;22(4):371-7.
3. Kutlu O, Karaaslan E, Karaosmanoglu N, Eksioglu HM. Evaluation of omalizumab at certain time intervals in patients with chronic spontaneous idiopathic urticaria. Int J Sci Rep. 2019;5(12):351-4.
4. Dziadecka WD, Grabarek B, Rajs KC, Mrozik SB. The analysis of the therapeutic potential of ustekinumab in psoriasis vulgaris treatment. Dermatol Ther. 2019;28:12843.
5. Cingoz O. Ustekinumab. MABs. 2009;1(3):216-21.
6. Gottlieb AB, Kalb RE, Langley RG, Krueger GG, Jong EM. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol. 2014;13(12):1441-8.
7. Papp K, Gottlieb AB, Naldi L. Safety surveillance for ustekinumab and other psoriasis treatments from
8. Finlay AY, Khan G. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-6.
9. Lewis V, Finlay AY. 10 years’ experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc. 2004;9(2):169-80.
10. Finlay A, Khan GK, Lascombe DK, Salek MS. Validation of sickness impact profile and psoriasis disability index in psoriasis. British J Dermatology. 1990;123(6):751-6.
11. Lewis VJ, Finlay AY. Two decades experience of the Psoriasis Disability Index. Dermatology. 2005;210(4):261-8.
12. Liu L, Li S, Zhao Y, Zhang J, Chen G. Health state utilities and subjective well-being among psoriasis vulgaris patients in mainland China. Qual Life Res. 2018;27(5):1323-33.
13. Ichiyama S, Ito M, Funasaka Y, Abe M. Assessment of medication adherence and treatment satisfaction in Japanese patients with psoriasis of various severities. J Dermatol. 2018;45(6):727-31.
14. Jarrett P, Camargo CA, Coomarasamy C, Scragg R. A randomized, double-blind, placebo-controlled trial of the effect of monthly vitamin D supplementation in mild psoriasis. J Dermatolog Treat. 2018;29(4):324-8.
15. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486.
16. Grundy SM, Cleeman JL, Daniels SR, Donato KA, Eckel RH. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112(17):2735-52.
17. Krueger G, Ellis CN. Psoriasis recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol. 2005;53(1):94-100.
18. Kutlu O, Metin A. A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic. Dermatol Ther. 2020;24(8):4539-47.
19. Chamin F, Krueger JG. Psoriasis vulgaris: an interplay of T lymphocytes, dendritic cells, and inflammatory cytokines in pathogenesis.Curr Opin Rheumatol. 2004;16(4):331-7.
20. Shaker OG, Kostafa W, Essmat S, Halim AM, Komly EM. The role of interleukin-12 in the pathogenesis of psoriasis. Clinical Biochem. 2006;39(2):119-25.
21. Reddy M, Davis C, Wong J, Marsters P. Modulation of CLA, IL-12R, CD40L, and IL-2Rα expression

International Journal of Research in Dermatology | July-August 2020 | Vol 6 | Issue 4  Page 509
and inhibition of IL-12-and IL-23-induced cytokine secretion by CNTO 1275. Cell Immunol. 2007;247(1):1-11.
22. Kimball AB, Papp KA, Wasfi Y, Chan D. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013;27(12):1535-45.
23. Bonifati C, Berardesca E. Clinical outcome measures of psoriasis. Reumatismo. 2007;59(1):64-7.
24. Chen L, Tsai TF. HLA-Cw6 and psoriasis. Br J Dermatol. 2018;178(4):562-854.
25. Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs. 2013;22(8):993-1005.
26. Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71(1):141-50.
27. Boutet MA, Nerviani A, Afflitto G, Pitzalis C. Role of the IL-23/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints. Int J Mol Sci. 2018;19(2):530.
28. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE. Secukinumab in plaque psoriasis results of two phase 3 trials. N Eng J Med. 2014;371(4):326-38.
29. Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol. 2008;20(4):416-22.
30. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829-35.
31. Liakou AI, Zouboulis CC. Links and risks associated with psoriasis and metabolic syndrome. Psoriasis (Auckl). 2015;5:125-8.
32. Gelfand JM, Yeung H. Metabolic syndrome in patients with psoriatic disease. J Rheumatol Suppl. 2012;89:24-8.

Cite this article as: Kutlu O, Eksioglu HM. Evaluation of ustekinumab treatment in psoriasis and the potential effect of metabolic syndrome on treatment response: a single center retrospective study. Int J Res Dermatol 2020;6:505-10.